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Abstract
Background: Results from epidemiologic studies examining polyunsaturated fatty acids 
(PUFAs) and colorectal cancer (CRC) risk are inconsistent. Mendelian randomization may 
strengthen causal inference from observational studies. Given their shared metabolic pathway, 
examining the combined effects of aspirin/NSAID use with PUFAs could help elucidate an 
association between PUFAs and CRC risk.
Methods: Information was leveraged from GWAS regarding PUFA-associated single nucleotide 
polymorphisms (SNPs) to create weighted genetic scores (wGSs) representing genetically-
predicted circulating blood PUFAs for 11,016 non-Hispanic white CRC cases and 13,732 controls 
in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO). Associations per 
standard deviation increase in the wGS were estimated using unconditional logistic regression. 
Interactions between PUFA wGSs and aspirin/NSAID use on CRC risk were also examined.
Results: Modest CRC risk reductions were observed per standard deviation increase in 
circulating linoleic acid (ORLA=0.96; 95% CI=0.93–0.98; p=5.2×10−4), α-linolenic acid 
(ORALA=0.95; 95% CI=0.92–0.97; p=5.4×10−5); whereas modest increased risks were observed 
for arachidonic acid (ORAA=1.06; 95% CI=1.03–1.08; p=3.3×10−5), eicosapentaenoic 
(OREPA=1.04; 95% CI=1.01–1.07; p=2.5×10−3), and docosapentaenoic acids (ORDPA=1.03; 95% 
CI=1.01–1.06; p=1.2×10−2. Each of these effects were stronger among aspirin/NSAID non-users 
in the stratified analyses.
Conclusions: Our study suggests that higher circulating shorter-chain PUFAs (i.e., LA and 
ALA) were associated with reduced CRC risk, whereas longer-chain PUFAs (i.e., AA, EPA, and 
DPA) were associated with an increased CRC risk.
Impact: The interaction of PUFAs with aspirin/NSAID use indicates a shared CRC inflammatory 
pathway. Future research should continue to improve PUFA genetic instruments to elucidate the 
independent effects of PUFAs on CRC.
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INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide with an 
estimated 746,000 males and 614,000 females diagnosed in 2012.[1] Diet has been shown to 
play an important role in CRC development.[2,3] One nutrition-related inflammatory 
metabolite, prostaglandin E2 (PGE-2), is known to influence colorectal carcinogenesis[4] 
via promotion of tumor cell proliferation[5,6] and silencing of tumor suppressor and DNA 
repair genes.[7] PGE-2 is generated via metabolism of omega-6 polyunsaturated fatty acid 
(PUFA) arachidonic acid (AA) via the cyclooxygenase-2 (COX-2) enzyme[4] and is often 
overexpressed in CRC.[8,9] While omega-3 polyunsaturated fatty acids (PUFAs) are also 
metabolized by COX-2, they produce a different array of non-inflammatory eicosanoids 
which have not been implicated in carcinogenesis. Thus, PGE-2 levels may be competitively 
reduced by increasing levels of omega-3 PUFAs in the diet, which could be a potential 
strategy for CRC prevention.
Dietary intake of PUFAs have been studied in relation to CRC incidence; however, the 
results from epidemiologic investigations have been inconsistent.[10–12] One possible 
reason for these discrepancies in the epidemiologic literature may be related to error in 
accurately assessing dietary PUFA intake. For example, differential recall of dietary intake 
in case-control studies of CRC could lead to biased effect estimates. In cohort studies, 
repeated measurements would be ideal but are not feasible, and a pre-diagnostic 
measurement of PUFAs using an objective dietary biomarker may not accurately reflect 
dietary intake since the etiologically relevant period for CRC development is unclear. The 
observed inconsistencies could also be due to biases related to inappropriate confounding 
control, selection bias, or reverse causation. In addition to these methodologic 
considerations, it is important to consider aspirin and non-steroidal anti-inflammatory drug 
(NSAID) use in tandem with PUFAs given their shared metabolic pathway via COX-2 and 
resulting PGE-2 production. A limited number of studies have examined the interaction 
between PUFAs and aspirin/NSAID use on CRC risk with inconsistent results.[13,14]
The goal of our study was to estimate potentially unbiased associations between genetically-
predicted circulating PUFAs with CRC using the Mendelian randomization approach. The 
Mendelian randomization approach uses genetic variants as instrumental variables for an 
exposure, and given alleles are randomly assorted during conception (akin to a randomized 
trial), results from such analyses are less susceptible to confounding and other biases[15]. 
Our study was conducted among non-Hispanic whites using data from two large CRC 
consortia. Given the shared metabolism via COX-2, we further assessed the combined 
effects of genetically-predicted circulating PUFAs and aspirin/NSAID use on CRC risk.
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The current study leverages the Genetics and Epidemiology of Colorectal Cancer 
Consortium (GECCO) consortium and the Colon Cancer Family Registry (CCFR), a pooled 
dataset of 14 studies of CRC with a total of 11,018 cases and 13,735 controls, all European 
ancestry. Details regarding the characteristics of individual studies included in the 
consortium have been published.[16–18] Briefly, medical records, pathologic reports, or 
death certificates were used to confirm colorectal cancer cases. Genotyped SNPs that did not 
meet the following criteria were excluded: (1) call rate <98%; (2) lack of Hardy-Weinberg 
equilibrium in the controls (p<1×10−4); or (3) low minor allele frequencies.[16] All imputed 
SNPs had an R2>0.3. Additional details regarding genotyping are published elsewhere.[19] 
Our study used individual-level and summary statistics data from GECCO to conduct 
primary and sensitivity analyses. Additionally, summary statistics were available from the 
ColoRectal Transdisciplinary Study (CORECT) consortium, a pooled dataset comprised of 
17 studies with a total of 18,682 cases and 11,225 controls are included. Study-specific 
sample sizes and genotyping platforms are provided in Supplementary Table 1. All study 
participants provided written informed consent, and all studies included in the consortia 
were approved by their respective institutional review boards.
Instrumental variable selection
Single nucleotide polymorphisms (SNPs) identified from published omega-6 and omega-3 
PUFA GWAS conducted among individuals of European ancestry [20,21] were used as the 
genetic instruments for this Mendelian randomization analysis. The previous GWAS were 
conducted among the same individuals as part of the Cohorts for Heart and Aging Research 
in Genomic Epidemiology (i.e., CHARGE) Consortium. They reported associations between 
SNPs and plasma levels of omega-6 and omega-3 PUFAs (i.e., as a percentage of total fatty 
acids). The following nine SNPs were selected as they were all genome-wide significant 
(i.e., p<5×10−8) and independent at r2<0.1: rs10740118, rs174547, rs2727270, rs16966952, 
rs3798713, rs174538, rs780094, rs3734398, and rs2236212. The SNPs used in the six 
different genetic instruments (one instrument per PUFA) are summarized in Table 1, and 
further details are provided in Supplementary Table 2. Using the β estimates and effect allele 
frequencies (EAFs) specific to each SNP i, and the variance in PUFA levels from published 
GWAS [20,21], the percent variation explained by the n SNPs included in the six different 
genetic instruments were calculated as follows: 
∑i
n 2βi2 MAF 1 − MAF /variance PUFA *100 [22]. In GECCO, the average imputation 
quality for imputed SNPs was r2=0.98 (range: 0.97–0.99). In CORECT, the average 
imputation quality was r2=0.99 (range: 0.98–0.99).
Construction of weighted genetic scores
Weighted genetic scores (wGSs) were created using individual-level genotyped data in 
GECCO. For each PUFA, a wGS was constructed per individual as follows: 
wGS = ∑i
nβi*dosagei; where n is the number of independent SNPs used for each PUFA 
instrument, βi is the effect estimate (i.e., increase in percent of total plasma fatty acids) for 
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SNP i (obtained from two GWAS examining omega-3 and omega-6 PUFAs within the same 
population [20,21]), and dosagei (range from 0–2) is the number of the effect alleles (i.e., 
alleles representing increased fatty acids levels) an individual possesses for SNP i. All 
GECCO participants had six different PUFA wGSs representing genetically-predicted 
circulating PUFA levels measured as a percentage of total plasma fatty acids. Excluding 
DHA’s correlation with LA, AA, and ALA, the PUFA wGSs were highly correlated 
(Supplementary Table 3). No wGSs were simultaneously included in a single model.
Statistical analysis
Unconditional logistic regression adjusted for age, sex, study, and top three principal 
components for European ancestry was conducted to estimate associations between one 
standard deviation increase in genetically-predicted circulating PUFAs and CRC risk in 
GECCO. Matching factors including age, sex, and study were included in the models to 
avoid any bias due to control selection.[23] We also adjusted for principal components of 
European ancestry to account bias due to population stratification.[24,25] We also explored 
the association between each PUFA wGS with potential confounders including education 
(highest level completed), family history (first-degree relative), regular aspirin/NSAID use 
(at any point during a participant’s lifetime), body mass index (BMI; kg/m2), ever smoking 
(yes/no), alcohol use (g/day; compared to non-drinkers), folate intake (μg/day from diet), red 
meat consumption (serving/day), fruit and vegetable intake (servings/day), and sedentary 
behavior (hours/week; Supplementary Table 4). Only education, family history, aspirin/
NSAID use, BMI, and fruit intake were found to be significantly associated (p<0.05) with 
the six different PUFA wGSs. Results from the fully-adjusted model adjusting for these 
covariates were identical to those from the minimally-adjusted models.
Analyses were stratified by potential effect measure modifiers including sex, age [i.e., <65 
years (median age), ≥65 years], smoking use, regular aspirin/NSAID use, and BMI (i.e., 
≤18.5 kg/m2, 18.5–24.9, 25–30, and >30). Statistically significant differences (p<0.05) in 
strata were assessed via the likelihood ratio test using nested models for the multiplicative 
interaction term. Polytomous regression was conducted to estimate stratum-specific 
estimates by cancer site (i.e., rectal vs. colon, and separately for proximal and distal colon 
cancer).
Additive interactions were also conducted to assess the combined effects of genetically-
predicted circulating PUFA levels and aspirin/NSAID use on CRC risk. All six PUFA-
specific wGSs were dichotomized at the median representing “low” and “high” circulating 
levels. Using a common referent category, additive interactions were assessed statistically 
via calculation of the relative excess risk due to interaction (RERI) and its corresponding 
95% confidence intervals.[26] All analyses were conducted using SAS Enterprise 7.13 
(Cary, NC, USA) and “TwoSampleMR” package curated by MR-Base [27] in R 3.5.1 (R 
Foundation for Statistical Computing; https://www.r-project.org/).
Sensitivity analyses
Several sensitivity analyses were conducted in GECCO and CORECT. A fixed-effects 
inverse-variance weighted Mendelian randomization analysis[28] was conducted using 
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summary statistics from PUFA GWAS and from the two consortia, GECCO and CORECT. 
The remaining analyses assessed the validity of the genetic instruments utilized in this study. 
Egger regression estimated a bias-reduced Mendelian randomization association in the 
presence of directional pleiotropy (i.e., when the average pleiotropic effects of all SNPs used 
in the instrument are either positive or negative), provided the effects of the instrument on 
the exposure is not correlated with any pleiotropic effects. Statistically significant intercepts 
from Egger regression indicate directional pleiotropy and was applied when three or more 
independent SNPs were included in the instrument (LA and DPA).[29] The weighted-
median approach estimated the Mendelian randomization effect assuming at least 50% of 
SNPs used in the genetic instrument are invalid.[30] Corresponding 95% confidence 
intervals for the weighted-median estimate were calculated using bootstrapped standard 
errors. The weighted-median estimate was only conducted for the PUFAs with more than 
two SNPs in the instrument, and was not conducted for AA, ALA, DPA, or DHA. The 
multivariable Mendelian randomization was adjusted for the potential pleiotropic effects of 
the SNPs included in one PUFA instrument on circulating levels of other PUFAs and utilized 
all nine GWAS-identified SNPs and their PUFA-specific beta estimates.[31,32] Finally, for 
instruments with more than two SNPs, a “leave-one-out” analysis was conducted where the 
inverse-variance MR association was re-estimated after excluding the most influential SNP 
(determined via largest magnitude change in MR estimate after exclusion).[27] All 
sensitivity analyses using summary statistics were scaled to represent one standard deviation 
increase in genetically-predicted circulating PUFA levels.
RESULTS
The variants used in the six different PUFA genetic instruments are listed in Table 1. The 
instruments for α-linolenic acid (ALA) and docosahexaenoic acid (DHA) included one SNP 
each explaining 1.0% (i.e., rs174547) and 0.7% (i.e., rs2236212) percent of variation in 
PUFA levels, respectively. The instruments for eicosapentaenoic acid (EPA) and 
docosapentaenoic acid (DPA) explained a higher proportion of variance in fatty acid levels 
with 2.1% and 11.6%, respectively. Comparatively, the SNPs associated with omega-6 
PUFAs, linoleic acid (LA) and arachidonic acid (AA), explained a higher percent variation 
in fatty acid levels. Four SNPs were significantly associated with and explained anywhere 
between 8.8 to 23.6% of the variation in circulating LA levels (reported range from studies 
included in the omega-6 GWAS [20]). For AA, two SNPs (i.e., rs174547 and rs16966952) 
together explained more than 33% of variation in AA fatty acid levels, with rs174547 
accounting for most of the variation explained.
Main effects and stratified analyses
In Table 2, a one standard deviation increase in wGSs for shorter-chain omega-6 and 
omega-3 fatty acids (i.e., LA and ALA) was associated with 4% to 5% reduced CRC risk 
(ORLA=0.96, 95% CI=0.93–0.98, p=5.2×10−4; ORALA=0.95, 95% CI=0.92–0.97, 
p=5.4×10−5). An increased CRC risk was observed per standard deviation increase in 
circulating longer-chain omega-3 fatty acids, EPA (OREPA=1.04, 95% CI=1.01–1.07, 
p=2.5×10−3) and DPA (ORDPA=1.03, 95% CI=1.01–1.06, p=1.2×10−2). No association was 
observed for DHA. The largest observed increased risk was for AA, the longer-chain 
Khankari et al. Page 5













omega-6 PUFA, where a 6% increased CRC risk was observed (ORAA=1.06, 95% CI=1.03–
1.08, p=3.3×10−5).
Stratified analyses are also presented in Table 2. Overall, most associations showed little 
evidence for varying by strata of different effect measure modifiers. Potential exceptions 
included a statistically significant multiplicative interaction for age (<65 years vs. ≥65 years; 
pinteraction for LA=1.5×10−2 and pinteraction for ALA=0.04) and regular aspirin/NSAID use 
(pinteraction for AA=0.05, pinteraction for ALA=0.04, and pinteraction for EPA=1.4×10−2). Among 
those ≥65 years, one standard deviation increase in genetically-predicted circulating ALA 
and LA reduced CRC risk by 7% and 8%, respectively (ORLA, ≥65 years=0.93, 95% CI=0.89–
0.96, p=5.4×10−5; ORALA, ≥65 years=0.92, 95% CI=0.89–0.96, p=2.7×10−5). Whereas among 
individuals <65 years, no statistically significant associations were observed. For longer-
chain omega-3 PUFAs (i.e., EPA, DPA, and DHA), no differences across the age-stratified 
results were observed. For the longer-chain omega-6, one standard deviation increase in 
circulating AA levels was associated with an 8% increased CRC risk among those ≥65 years 
(ORAA, ≥65 years=1.08, 95% CI=1.04–1.12, p=2.7×10−5), and no association was observed 
among those <65 years (ORAA, <65 years=1.03, 95% CI=0.99–1.07, p=0.08). Among aspirin/
NSAIDs non-users, a similar 8% increased risk was observed per standard deviation increase 
in circulating AA (ORAA, aspirin/NSAID non-user=1.08, 95% CI=1.04–1.11, p=8.3×10−6), 
whereas no association was observed (ORAA, aspirin/NSAID user=1.02, 95% CI=0.98–1.07, 
p=0.34) among users. For the short-chain omega-3 PUFA ALA, those individuals who were 
aspirin/NSAID non-users were observed to have a 7% reduced CRC risk per one standard 
deviation increase in circulating ALA levels (ORALA, aspirin/NSAID non-user=0.93, 95% 
CI=0.90–0.96, p=9.7×10−6). Similar to longer-chain omega-6 AA, increased CRC risks were 
observed for higher levels of circulating longer-chain omega-3s EPA 
(OREPA, aspirin/NSAID non-user=1.07, 95% CI=1.03–1.10, p=1.7×10−4) and DPA 
(ORDPA, aspirin/NSAID non-user=1.05, 95% CI=1.02–1.09, p=2.4×10−3) among aspirin/NSAID 
non-users; however this multiplicative interaction was only statistically significant for EPA. 
Whereas among regular aspirin/NSAID users, null associations were observed for PUFAs in 
the stratified analysis.
Additive interaction with aspirin/NSAID use
In Table 3, additive interaction between PUFA-specific wGSs and regular use of aspirin/
NSAID via a common referent category (i.e., “low” circulating PUFA levels and aspirin/
NSAID non-users) are presented. Among those who were not regular aspirin/NSAID users 
(i.e., aspirin/NSAID non-users), high levels of circulating shorter-chain PUFAs (i.e., 
omega-6 LA and omega-3 ALA) was associated with an 11–13% reduction in CRC risk 
(ORhigh LA, aspirin/NSAID non-user=0.89, 95% CI=0.84–0.95, p=7.8×10−4; ORhigh ALA, 
aspirin/NSAID non-user=0.87, 95% CI=0.81–0.93, p=4.1×10−5). A 15% increased CRC risk was 
observed for higher levels of genetically-predicted circulating longer-chain omega-6 AA 
among aspirin/NSAID non-users (ORAA, aspirin/NSAID non-user=1.15, 95% CI=1.07–1.23, 
p=4.4×10−5). Similar increased CRC risks were observed for higher circulating levels of 
longer-chain omega-3 PUFAs EPA (OREPA, aspirin/NSAID non-user=1.12, 95% CI=1.05–1.20, 
p=7.6×10−4) and DPA (ORDPA, aspirin/NSAID non-user=1.07, 95% CI=1.00–1.15, p=3.9×10−2), 
among aspirin/NSAID non-users.
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Among those with lower levels of genetically-predicted circulating PUFAs, use of aspirin/
NSAIDs was associated with reduced CRC risk, with CRC risk reductions ranging from 
24% (ORlow AA, aspirin/NSAID user=0.76, 95% CI=0.70–0.82, p=8.4×10−12) to 29% 
(ORlow LA, aspirin/NSAID user=0.71, 95% CI=0.65–0.77, p=3.3×10−17). Generally, among 
aspirin/NSAID users, higher levels of genetically-predicted PUFAs (namely LA and ALA) 
did not further reduce CRC risk compared to lower levels of PUFAs 
(ORhigh LA, aspirin/NSAID user=0.68, 95% CI=0.63–0.73, p=2.0×10−20; 
ORhigh ALA, aspirin/NSAID user=0.65, 95% CI=0.65, 95% CI=0.60–0.71, p=3.2×10−25). For 
longer-chain PUFAs (i.e., omega-6: AA, and omega-3s: EPA, DPA, and DHA), among 
aspirin/NSAID users, the effect of higher circulating levels of these PUFAs modestly 
attenuated the CRC risk reductions observed compared to lower levels of AA, EPA, DPA, 
and DHA. However, the additive interactions presented did not significantly deviate from an 
additive model as measured via the RERI and corresponding 95% CIs. Overall, CRC risk 
reductions (likely driven by aspirin/NSAID use) were still observed in this subgroup 
(ORhigh AA, aspirin/NSAID user=0.82, 95% CI=0.76–0.89, p=1.9×10−6; 
ORhigh EPA, aspirin/NSAID user=0.80, 95% CI=0.74–0.87, p=4.4×10−8; 
ORhigh DPA, aspirin/NSAID user=0.77, 95% CI=0.71–0.83, p=8.1×10−11; 
ORhigh DHA, aspirin/NSAID user=0.80, 95% CI=0.73–0.87, p=2.5×10−7).
Summary statistics and sensitivity analyses results
The inverse-variance weighted fixed-effects Mendelian randomization results 
(Supplementary Table 5) using summary statistics were identical to those from the 
individual-level wGS results. For PUFAs with more than one SNP included in the 
instrument, statistically significant heterogeneity was observed for the inverse-variance 
weighted fixed-effects MR estimates for DPA (pheterogeneity=3.6×10−4), indicating possibility 
for directional pleiotropy (i.e., when the effect on the outcome for each SNP included in the 
instrument is in the same direction).[15] The results in CORECT were identical to GECCO. 
Results from the weighted-median analyses were identical to the inverse-variance weighted 
fixed-effects MR, indicating that our estimates are robust when assuming half the variants 
included in the instrument are invalid.[30] No estimates from the multivariable MR 
approaches were statistically significant, which evaluated potential pleiotropy of SNPs 
included in one instrument on other PUFAs.[31,32] Results from the “leave-one-out” 
analysis (only possible for LA and DPA) indicated that rs174547 was the most influential 
SNP in these two instruments, and removal of rs174547 from the PUFA instruments did not 
affect the overall results. The one exception being for DPA in the CORECT consortium 
where removal of rs174547 resulted in a 7% reduced CRC risk (ORDPA=0.93, 95% 
CI=0.88–0.97, p=2.1×10−3).
DISCUSSION
In our study conducted among over 24,000 non-Hispanic white individuals from the 
GECCO consortium, we observed a 6% increased CRC risk among those with higher 
genetically-predicted circulating levels of omega-6 PUFA AA. Modest increased risks were 
observed for EPA and DPA. Modest risk reductions were observed for longer-chain omega-6 
PUFA LA, and longer-chain omega-3 PUFAs ALA. These associations remained statistically 
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significant among those ≥65 years and among aspirin/NSAID non-users. When stratified by 
aspirin/NSAID use, one standard deviation increase in circulating AA increased risk of CRC 
by 8% (pinteraction=0.05), and reduced risk by 7% for ALA (pinteraction=0.04). Regular users 
of aspirin/NSAIDs were observed to have 18–35% reduced risk of CRC regardless of their 
genetically-predicted levels of PUFAs. Our main effects results were confirmed using the 
summary statistics Mendelian randomization approach.
Not all the associations observed were consistent with our biologic hypothesis regarding 
omega-6 and omega-3 PUFAs. For example, a modest 4% reduction in CRC risk was 
observed for increases in genetically-predicted short-chain omega-6 LA levels, which is a 
pre-cursor to AA levels and subsequently PGE-2. One potential explanation for the risk 
reduction observed for the LA may be related to two variants included in the instrument that 
are part of the FADS1 and FADS2 genes (i.e., rs174547 and rs2727270, respectively) and 
are responsible for the conversion of LA to AA. When incorporating these SNPs in the 
instrument, increased genetically-predicted levels of LA will result in lower downstream 
levels of AA and PGE-2, which could potentially reduce CRC risk. We also observed 
modest increased risks for higher genetically-predicted levels of potentially anti-
inflammatory omega-3 PUFAs EPA and DPA. However, the risk reduction is consistent with 
a previous meta-analysis of LA intake on CRC risk[33], and with a previous Mendelian 
randomization study (also included data from the CCFR) conducted by May-Wilson et al. 
among 7 European cohorts (ORLA=0.95, 95% CI= 0.93–0.98).[34] Furthermore, results for 
AA from May-Wilson et al. (ORAA=1.05, 95% CI=1.02–1.07) are nearly identical to those 
presented in our study. Results for EPA, DPA, and DHA were in the same direction (except 
for EPA); however, the effect sizes reported in May-Wilson et al. have larger magnitudes but 
are less precise. We also observed slightly stronger associations among older (i.e., ≥65 
years) compared to younger individuals for many of the PUFAs, which could be an 
indication of the cumulative effects of being genetically-predisposed to higher PUFA levels 
on CRC risk.
The benefits of taking aspirin/NSAID on CRC risk has been studied extensively.[35,36] 
GECCO has also reported risk reductions with aspirin/NSAID use (OR=0.71, 95% CI=0.66–
0.77),[37] and the magnitude of the risk reduction was similar to the associations reported 
among the subgroup of aspirin/NSAID users when considering the interactions with 
circulating PUFAs. Notably, in the Nurses’ Health Study, long-term aspirin use (i.e., >10 
years) and NSAID use reduced CRC risk by 32%, and risk was reduced by over 50% 
(OR=0.47, 95% CI=0.31–0.71) among women taking more than 14 (325-mg) tablets per 
week.[35] The benefits of long-term aspirin use were corroborated in randomized and 
observational studies.[36] The recommendation to the United States Preventive Task Force 
for long-term aspirin use as a preventive strategy for CRC was indicated for 10 years post-
initiation.[38] In our study, aspirin/NSAID use was defined as regular use over an 
individual’s lifetime and this definition varied according to study. Thus, it is possible that 
heterogeneity in assessment of aspirin intake may affect the association between long-term 
aspirin use and CRC risk in our study; however, the associations observed are consistent 
with previous investigations.
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Hall and colleagues examined the interaction between PUFA levels and aspirin use on CRC 
risk among men in the Physicians’ Health Study.[14] They reported reduced CRC risk with 
higher intake of long-chain omega-3 PUFAs (i.e., Quartile 4 vs. Quartile 1, ORQ4vs.Q1=0.34, 
95% CI=0.15–0.82) among non-aspirin users. Similar to our results, the potential added 
benefit of increasing long-chain omega-3 intake among aspirin users was minimal when 
compared to non-aspirin users with low omega-3 intake.[14] Among the Nurses’ Health 
Study and Health Professionals Follow-up Study participants, the potential modification of 
marine omega-3 dietary intake by aspirin/NSAID use on CRC risk was evaluated but no 
significant heterogeneity was reported.[13] Another study examined pre-diagnostic levels of 
the urinary PGE-2 metabolite (PGE-M) on colorectal adenoma risk stratified by aspirin use 
(>2 tablets per week) in the Nurses’ Health Study.[39] Aspirin use was only beneficial 
among individuals with high levels of PGE-M. Arachidonic acid uptake by COX-2 is 
reduced in the presence of NSAIDs in colon cancer cells.[40] Similarly, reduced binding of 
DHA to COX-2 was observed when combined with a selective COX-2 inhibitor celecoxib.
[41] Inhibition of PUFA metabolism via the COX-2 enzyme in the presence of aspirin may 
help to explain the potential antagonism observed for the interaction between PUFAs and 
aspirin on CRC risk.
Our study has several strengths. First, we utilized data from two large consortia of 
approximately 25,000 and 30,000 subjects (for GECCO and CORECT, respectively) to 
estimate potentially unbiased association between PUFAs and CRC risk using the Mendelian 
randomization approach. The availability of individual-level GECCO data and several 
covariates was helpful for assessing the association between the PUFA-specific wGSs with 
CRC risk factors. This is one way to assess the validity of the genetic instrument in a 
Mendelian randomization analysis (i.e., the instrument should not be associated with 
confounders of the exposure-disease association).[15] We adjusted for additional covariates 
that were found to be associated with the six different PUFA wGS; however, the results from 
the adjusted models were identical to the minimally-adjusted models. We also conducted 
stratified analyses to estimate the association between genetically-predicted PUFAs among 
different subgroups. Several Mendelian randomization sensitivity analyses were conducted 
to assess the robustness of the results in the presence of pleiotropy, but these analyses are 
likely underpowered due to the limited number of independent SNPs included. Finally, we 
are one of the few studies to assess the additive interaction between genetically-predicted 
circulating PUFAs along with aspirin/NSAID use on CRC risk.
While our study has many strengths, there are several opportunities for improvement in 
future investigations. There was indication of directional pleiotropy in the Mendelian 
randomization sensitivity analyses (for DPA), and for some of the PUFAs, we were unable to 
estimate an effect for sensitivity analyses using summary statistics (i.e., Egger regression, 
weighted-median approach, leave-one-out analysis) due to the limited number of SNPs used 
in the genetic instrument. Several of the wGSs were highly correlated with one another in 
the individual-level analysis, which would affect the estimation of independent PUFA 
effects. However, incorporating additional SNPs as part of the genetic instrument in the 
future will increase the percent variation explained and subsequently increase the strength of 
the genetic instrument. Stronger genetic instruments will ultimately help to further elucidate 
independent PUFA effects and provide a better opportunity to assess influence of pleiotropy 
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on the Mendelian randomization estimates. Furthermore, using new weights from future 
GWAS that examine associations with longer-term PUFA biomarkers (e.g., adipose tissue 
and red blood cell) will help to clarify the potential causal role of PUFAs on CRC risk. The 
power to detect an OR at least 1.05 at an α=0.05 in our study ranged from approximately 
5% (for DHA) to 62% (for AA), and is dependent upon the strength of the instrument.[42] 
Further, increasing the percent variation explained may allow for the detection of even 
smaller effects due to increased power. The associations derived from a Mendelian 
randomization analysis could help to identify the presence of a potential causal association 
between exposure and outcome. Many comparisons were made in this analysis and thus the 
potential for false-positive associations exists. However, most associations in our analysis 
remain statistically significant even after Bonferroni correction for multiple comparisons. 
Furthermore, our genetic instruments utilized SNPs previously reported to be associated 
with circulating PUFAs that have previously shown to have influence on carcinogenesis in 
experimental studies, and thus the analyses undertaken in this paper are based on an a priori 
biologic hypothesis. Finally, it would be worthwhile to conduct similar analyses in different 
populations to better understand the influence of PUFAs on CRC risk in populations where 
the ratio of omega-6 to omega-3 PUFAs may differ (e.g., Asians), and among populations 
where CRC risk is high (e.g., African Americans). Future investigations should consider 
identifying additional genetic variants associated with PUFA levels among different races 
which would facilitate conducting Mendelian randomization analyses in these populations.
Due to substantial amount of missing data for continuous measures of aspirin/NSAID use, 
we were unable examine the interaction between long-term aspirin/NSAID use and 
circulating PUFAs on CRC risk. However, since selective COX-2 inhibitors may increase 
risk of cardiovascular disease with long-term use,[43] examining the potential added benefit 
of omega-3 PUFA intake with long-term use of selective COX-2 inhibitors may be futile 
realistically (unless among high-risk population subgroups). Finally, it is possible that the 
results from the additive interaction are subject to residual confounding given aspirin/
NSAID use was self-reported.[44] Thus, future investigations with better long-term 
measures of aspirin/NSAID use should further examine the interaction with PUFAs, and also 
consider other potential biologic pathways.
In conclusion, we observed a 6% increased risk for CRC among those with higher 
genetically-predicted circulating levels of omega-6 PUFA AA, and similarly modest 
increased risks for longer-chain omega-3 PUFAs EPA and DPA. Risk reductions were 
observed among those with higher genetically-predicted circulating levels of short-chain 
omega-6 PUFA LA, and short-chain omega-3 PUFA ALA. Our study results indicate that 
among aspirin/NSAID users, the potential benefit of increasing long-chain omega-3 PUFAs 
may be minimal in terms of further reducing CRC risk. Results from the Mendelian 
randomization analysis using summary statistics corroborate our main effect findings. 
However, due to the limited number of variants used in some genetic instruments, an 
assessment of the influence of pleiotropy on our estimates could not be evaluated for all 
PUFAs. Given the small effects observed and the limited number of SNPs used in our 
genetic instruments, the clinical significance of our results is limited, and our results may 
only indicate a shared CRC inflammatory pathway for PUFAs and aspirin/NSAID use. 
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Future Mendelian randomization studies should continue to improve the genetic instruments 
used which will help to further elucidate the effects of specific PUFAs on CRC risk.
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Table 1.
Single nucleotide polymorphisms (SNPs) identified from published genome-wide association studies (GWAS) 
used to construct genetic instruments for polyunsaturated fatty acids (PUFA)












 Linoleic acid (LA; 18:2) 4 8.8 – 23.6 1.18
rs10740118, rs174547, 
rs2727270, rs16966952
 Arachidonic acid (AA; 20:2) 2 33.1 1.11 rs174547, rs16966952
Omega-3
 α-linolenic acid (ALA; 18:3) 1 1.0 0.01 rs174547
 Eicosapentaenoic acid (EPA; 20:5) 2 2.1 0.06 rs3798713, rs174538
 Docosapentaenoic acid (DPA; 22:5) 3 11.6 0.06
rs780094, rs3734398, 
rs174547
 Docosahexaenoic acid (DHA; 22:6) 1 0.7 0.08 rs2236212
a
Percent variation explained per instrument calculated as follows: ∑i
n 2βi2 MAF 1 − MAF /variance PUFA *100, where n is the 
number of independent SNPs, β is effect estimate from GWAS, MAF is the minor allele frequency, and variance is PUFA-specific.[22]
b
Each PUFA-specific weighted-genetic score (wGS) represents a genetically-predicted level of PUFAs, which represent an increase in total percent 
of plasma fatty acids. Weights used to create the wGS were obtained from previous genome-wide association studies (GWAS).[20,21]
c
SNPs used in each instrument are independent with linkage disequilibrium (LD; as measured using the correlation coefficient, r2) less than 0.1.
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Table 3.
Additive interaction between genetically-predicted polyunsaturated fatty acid (PUFA) intake and regular 
aspirin/NSAID use in the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO)




use Cases / Controls OR





 Low No 3,590 / 3,722 1.00
 High No 3,329 / 3,950 0.89 0.84–0.95 7.8×10−4
 Low Yes 1,545 / 2,505 0.71 0.65–0.77 3.3×10−17




 Low No 3,321 / 4,002 1.00
 High No 3,598 / 3,670 1.15 1.07–1.23 4.4×10−5
 Low Yes 1,505 / 2,619 0.76 0.70–0.82 8.4×10−12




 Low No 3,603 / 3,667 1.00
 High No 3,316 / 4,005 0.87 0.81–0.93 4.1×10−5
 Low Yes 1,566 / 2,437 0.72 0.67–0.78 2.4×10−15




 Low No 4,046 / 4,476 1.00
 High No 2,873 / 3,196 1.12 1.05–1.20 7.6×10−4
 Low Yes 1,807 / 3,111 0.76 0.70–0.82 1.9×10−11




 Low No 3,848 / 4,105 1.00
 High No 3,071 / 3,567 1.07 1.00–1.15 3.9×10−2
 Low Yes 1,665 / 2,706 0.76 0.70–0.82 8.2×10−12




 Low No 4,052 / 4,627 1.00
 High No 2,867 / 3,045 1.05 0.98–1.13 0.13
 Low Yes 1,806 / 3,140 0.72 0.67–0.78 5.1×10−18




Genetically-predicted polyunsaturated fatty acid intake dichotomized at the median (i.e., wGS < median = “Low” and wGS ≥ median = “High”).
b
All models adjusted for age, sex, study, and top principal components for European ancestry.
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c
Additive interaction assessed using the Relative Excess Risk due to Interaction (RERI) = OR11 – OR10 – OR01 + 1 (e.g., Linoleic acid RERI = 
0.68 – 0.71 – 0.89 + 1 = 0.08).
d
95% CI for RERI estimated using method of Hosmer & Lemeshow.[26]
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